Research programme: lobeline analogues - Yaupon Therapeutics

Drug Profile

Research programme: lobeline analogues - Yaupon Therapeutics

Alternative Names: Lobelane

Latest Information Update: 12 Jan 2012

Price : $50

At a glance

  • Originator Yaupon Therapeutics
  • Developer Ceptaris Therapeutics
  • Class
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Drug abuse

Most Recent Events

  • 08 Jan 2012 Discontinued - Preclinical for Drug abuse in USA (unspecified route)
  • 07 Nov 2007 Preclinical trials in Drug abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top